$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

$swtx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000177342723000018 Filed on May 03, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$46.99M	$44.18M
YoY Change	51.64%	61.42%
% of Gross Profit
Research & Development	$35.86M	$33.52M
YoY Change	-5.7%	-1.7%
% of Gross Profit
Depreciation & Amortization	$382.0K	$253.0K
YoY Change	101.05%	134.26%
% of Gross Profit
Operating Expenses	$82.85M	$77.70M
YoY Change	20.06%	26.4%
Operating Profit	-$82.85M	-$77.70M
YoY Change	20.06%	26.4%
Interest Expense	$5.030M	$4.478M
YoY Change	-33633.33%	-3321.58%
% of Operating Profit
Other Income/Expense, Net	$5.828M	$5.557M
YoY Change	1574.71%	111040.0%
Pretax Income	-$77.93M	-$73.42M
YoY Change	12.86%	18.8%
Income Tax
% Of Pretax Income
Net Earnings	-$77.93M	-$73.42M
YoY Change	12.85%	18.8%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.25	-$1.18
Diluted Earnings Per Share	-$1.25	-$1.18
COMMON SHARES
Basic Shares Outstanding	62.52M shares	62.50M shares
Diluted Shares Outstanding	62.46M shares	62.33M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$476.7M	$528.1M
YoY Change	42.5%	51.65%
Cash & Equivalents	$115.0M	$102.4M
Short-Term Investments	$361.7M	$425.7M
Other Short-Term Assets	$7.194M	$9.516M
YoY Change	-3.54%	23.91%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$483.9M	$537.7M
YoY Change	41.49%	51.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.00M	$15.73M
YoY Change	171.96%	160.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$4.814M	$5.714M
YoY Change	-24.28%	124.43%
Other Assets	$3.613M	$2.891M
YoY Change	34.46%	10.05%
Total Long-Term Assets	$33.43M	$31.54M
YoY Change	39.75%	-36.45%
TOTAL ASSETS
Total Short-Term Assets	$483.9M	$537.7M
Total Long-Term Assets	$33.43M	$31.54M
Total Assets	$517.3M	$569.2M
YoY Change	41.38%	40.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.454M	$6.990M
YoY Change	57.64%	322.61%
Accrued Expenses	$36.09M	$28.69M
YoY Change	12.05%	34.95%
Deferred Revenue	$2.364M	$1.690M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$41.91M	$37.75M
YoY Change	20.04%	62.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$23.98M	$24.52M
YoY Change	354.9%	345.82%
Total Long-Term Liabilities	$23.98M	$24.52M
YoY Change	354.9%	342.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.91M	$37.75M
Total Long-Term Liabilities	$23.98M	$24.52M
Total Liabilities	$65.89M	$62.27M
YoY Change	63.96%	116.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$721.3M	-$643.4M
YoY Change	70.36%	81.6%
Common Stock	$6.000K	$6.000K
YoY Change	20.0%	20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$451.4M	$506.9M
YoY Change
Total Liabilities & Shareholders Equity	$517.3M	$569.2M
YoY Change	41.38%	40.34%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$77.93M	-$73.42M
YoY Change	12.85%	18.8%
Depreciation, Depletion And Amortization	$382.0K	$253.0K
YoY Change	101.05%	134.26%
Cash From Operating Activities	-$47.81M	-$61.82M
YoY Change	22.37%	26.97%
INVESTING ACTIVITIES
Capital Expenditures	$3.088M	$2.977M
YoY Change	-222.3%	24.72%
Acquisitions
YoY Change
Other Investing Activities	$63.84M	$101.6M
YoY Change	118.03%	252.58%
Cash From Investing Activities	$60.76M	$98.60M
YoY Change	127.07%	273.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-342.0K	-$1.848M
YoY Change	288.64%	-808.05%
NET CHANGE
Cash From Operating Activities	-47.81M	-$61.82M
Cash From Investing Activities	60.76M	$98.60M
Cash From Financing Activities	-342.0K	-$1.848M
Net Change In Cash	12.60M	$34.94M
YoY Change	-201.62%	-258.79%
FREE CASH FLOW
Cash From Operating Activities	-$47.81M	-$61.82M
Capital Expenditures	$3.088M	$2.977M
Free Cash Flow	-$50.90M	-$64.80M
YoY Change	39.27%	26.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39044
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001773427
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	SPRINGWORKS THERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-4066827
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Washington Blvd
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
CY2023Q1	dei	City Area Code CityAreaCode	203
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	883-9490
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	SWTX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62523060	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102401000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67490000	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	425740000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	524722000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	9516000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7548000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	537657000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	599760000	usd
CY2023Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4794000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15728000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13571000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6602000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4698000	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	5714000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	4193000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	605000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	578000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2891000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2648000	usd
CY2023Q1	us-gaap	Assets Assets	569197000	usd
CY2022Q4	us-gaap	Assets Assets	630242000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6990000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8010000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28687000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39242000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	386000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	483000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1690000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3314000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	37753000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51049000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6664000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4768000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	17856000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16233000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	62273000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	72050000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62623777	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62453328	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62523438	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62423129	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1153702000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1130224000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-643350000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-569930000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100339	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	30199	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	3272000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1341000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-162000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-767000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	506924000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	558192000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	569197000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	630242000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33524000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34103000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44175000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27366000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	77699000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	61469000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-77699000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-61469000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-199000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-193000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	5756000	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	198000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5557000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1278000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-337000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-73420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.18
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.18
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.26
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.26
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62326992	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62326992	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48937756	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48937756	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-73420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	605000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1146000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	605000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1146000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72815000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62947000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	422396000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17094000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1167000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	906000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1146000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	376804000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	558192000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23395000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	83000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1931000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	605000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-73420000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	506924000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-73420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-61801000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	253000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	108000	usd
CY2023Q1	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	286000	usd
CY2022Q1	swtx	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	272000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	23395000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	17094000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1278000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-337000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1968000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1729000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	243000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-82000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-753000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1770000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10255000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4695000	usd
CY2023Q1	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-391000	usd
CY2022Q1	swtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-44000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61818000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48688000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2977000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2387000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2800000	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	68148000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23242000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	172529000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	52053000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	98604000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26424000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1931000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	906000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1167000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1848000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	261000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	34938000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-22003000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68068000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104526000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103006000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82523000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2136000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5580000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing programs in both rare tumor types as well as highly prevalent, genetically defined cancers. Two of the programs are late-stage clinical product candidates: nirogacestat and mirdametinib. In December 2022, the Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for nirogacestat for the treatment of adults with desmoid tumors. In February 2023, the NDA filing was accepted by the FDA and granted priority review with an assigned Prescription Drug User Fee Act, or PDUFA, target action date of August 27, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of $643.4 million and $569.9 million, and working capital of $499.9 million and $548.7 million, as of March 31, 2023 and December 31, 2022, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company’s development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, consultants and vendors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash, cash equivalents and marketable securities of $528.1 million and $597.0 million as of March 31, 2023 and December 31, 2022, respectively. Based on the Company's cash, cash equivalents and marketable securities as of March 31, 2023, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve months after the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Coronavirus, or COVID-19, including emerging variant strains of COVID-19, has continued to spread in the areas in which the Company operates. The Company's response has evolved over the course of the ongoing COVID-19 pandemic, and the Company has largely resumed normal operations. In the United States, the government has announced a plan for the expiration of the federal Public Health Emergency and national emergency declarations for COVID-19 in May 2023. During the periods presented, the Company did not experience any material disruptions to the execution of research and development or commercialization preparation activities; however, as a result of the COVID-19 pandemic, or any impacts of emerging variant strains of the COVID-19 virus, stagnant vaccination rates and related factors, the Company may experience disruptions that could impact its research and development and commercialization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">timelines and outcomes. The Company will continue to evaluate the impact of the ongoing COVID-19 pandemic, along with the impact of emerging variants, on its business. While the extent to which the ongoing COVID-19 pandemic impacts the Company’s future results will depend on future developments, the pandemic and associated impacts, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of emerging variant strains of the COVID-19 virus and the rollout of COVID-19 vaccines, all of which remain uncertain and difficult to predict, could result in a material impact to the Company’s business, prospects, future financial condition, results of operations and cash flows.</span></div>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-643400000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-569900000	usd
CY2023Q1	swtx	Working Capital WorkingCapital	499900000	usd
CY2022Q4	swtx	Working Capital WorkingCapital	548700000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	528100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	597000000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates and assumptions </span></div>reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the valuation of stock-based compensation awards. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	425902000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	162000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	425740000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	530283000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	767000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	529516000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1525000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1780000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9133000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19142000	usd
CY2023Q1	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	12009000	usd
CY2022Q4	swtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	12321000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6020000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5999000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28687000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39242000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	418000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1759000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1806000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1854000	usd
CY2023Q1	swtx	Lessee Operating Lease Liability Payments Due After Three Year LesseeOperatingLeaseLiabilityPaymentsDueAfterThreeYear	2550000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8387000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1337000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	7050000	usd
CY2023Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23395000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17094000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13488050	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8690989	shares

Files In Submission

Name	View Source	Status
0001773427-23-000018-index-headers.html	Edgar Link	pending
0001773427-23-000018-index.html	Edgar Link	pending
0001773427-23-000018.txt	Edgar Link	pending
0001773427-23-000018-xbrl.zip	Edgar Link	pending
exhibit101thirdamendedan.htm	Edgar Link	pending
exhibit101thirdamendedan001.jpg	Edgar Link	pending
exhibit101thirdamendedan002.jpg	Edgar Link	pending
exhibit101thirdamendedan003.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
swtx-20230331.htm	Edgar Link	pending
swtx-20230331.xsd	Edgar Link	pending
swtx-20230331xex311.htm	Edgar Link	pending
swtx-20230331xex312.htm	Edgar Link	pending
swtx-20230331xex321.htm	Edgar Link	pending
swtx-20230331xex322.htm	Edgar Link	pending
swtx-20230331_cal.xml	Edgar Link	unprocessable
swtx-20230331_def.xml	Edgar Link	unprocessable
swtx-20230331_pre.xml	Edgar Link	unprocessable
swtx-20230331_lab.xml	Edgar Link	unprocessable
swtx-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx

2023 Q2 Form 10-Q Financial Statement

#000177342723000018 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX SpringWorks Therapeutics, Inc. Stock $swtx

2023 Q2 Form 10-Q Financial Statement

#000177342723000018 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWTX
SpringWorks Therapeutics, Inc. Stock $swtx